Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.

Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, Akaike K, Hamada S, Jodai T, Nakashima K, Ishizuka S, Sato N, Saruwatari K, Saeki S, Tomita Y, Sakagami T.

J Clin Med. 2019 May 29;8(6). pii: E762. doi: 10.3390/jcm8060762.

2.

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.

Xia L, Liu Y, Wang Y.

Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.

3.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.

PMID:
30738221
4.

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.

Lecis D, Sangaletti S, Colombo MP, Chiodoni C.

Cancers (Basel). 2019 May 4;11(5). pii: E624. doi: 10.3390/cancers11050624. Review.

5.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

6.

Immunological Agents Used in Cancer Treatment.

Simsek M, Tekin SB, Bilici M.

Eurasian J Med. 2019 Feb;51(1):90-94. doi: 10.5152/eurasianjmed.2018.18194. Epub 2018 Nov 30. Review.

7.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol. 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022. [Epub ahead of print]

PMID:
31169866
8.

Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.

Takahashi T, Tateishi A, Bychkov A, Fukuoka J.

Int J Mol Sci. 2019 May 26;20(10). pii: E2578. doi: 10.3390/ijms20102578.

9.

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.

Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.

J Immunother Cancer. 2019 May 3;7(1):118. doi: 10.1186/s40425-019-0604-2.

10.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

PMID:
30242316
11.

Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.

Tan PS, Aguiar P Jr, Haaland B, Lopes G.

Lung Cancer. 2018 Jan;115:84-88. doi: 10.1016/j.lungcan.2017.11.017. Epub 2017 Nov 22.

PMID:
29290267
12.

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.

Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10.

PMID:
28646772
13.

Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.

Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, Ren S, Chen X, Zhou C.

Lung Cancer. 2019 Apr;130:10-17. doi: 10.1016/j.lungcan.2019.01.017. Epub 2019 Jan 31.

PMID:
30885328
14.

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.

Jaafar J, Fernandez E, Alwan H, Philippe J.

Endocr Connect. 2018 May;7(5):R196-R211. doi: 10.1530/EC-18-0079. Review.

15.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
16.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

17.

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.

J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.

18.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28. Erratum in: Cancer Immunol Res. 2018 Apr;6(4):498-499.

19.

Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).

Yoneda K, Imanishi N, Ichiki Y, Tanaka F.

J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173. Review.

20.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Herzberg B, Campo MJ, Gainor JF.

Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Review.

Supplemental Content

Support Center